Skip to main content

Qualifying for the Third Presidential Debate Just Got Harder for 2020 Democrats

With 23 Democrats vying for the 2020 presidential nomination, the Democratic National Committee is upping the threshold for candidates to appear in the third Democratic presidential debate.

The DNC announced Wednesday that ABC News and Univision will host the third debate on September 12, with the possibility of adding a second night on September 13 if enough candidates meet the new threshold.

To appear in the first and second debates in June and July, candidates must poll at at least 1% and have received donations from 65,000 donors with a minimum of 200 in at least 20 states. It will be even more challenging to qualify for the third debate: candidates will need to reach at least 2% in the polls and will need 130,000 individual donors with a minimum of 400 in at least 20 states.

The list of approved pollsters will change for the third debate. Not only will candidates need to hit 2% from four, rather than three, polls, but also Reuters and Las Vegas Review Journal have been removed from the list. The list still includes a range of other pollsters including the Associated Press, the major broadcast networks, New York Times, NPR, Wall Street Journal, Washington Post, and Quinnipiac University. Only polls published between June 28 and August 28 will count toward qualifying for the September debate.

These added criteria seek to whittle down the number of candidates as the Democratic primary approaches in 2020. Of the 23 announced candidates, 19 have already qualified for the first debate, which will be divided across two nights. The third debate will be capped at a total of 20 candidates, but the new threshold makes it unlikely that that many will qualify.

More must-read stories from Fortune:

--How civil rights and liberties activists are taking on Capitol Hill

--What exactly is ranked-choice voting?

--21 abortion restrictions have already been enacted in 2019

--Should Title VII civil rights protections include the LGBTQ community?

--Human Trafficking is an epidemic in the U.S. It’s also big business

Don’t miss the daily Term Sheet, Fortune‘s newsletter on deals and dealmakers.



from Fortune http://bit.ly/2KcJQSH
Labels:

Comments

Post a Comment

Popular posts from this blog

Photo finish: Crashing sales force Olympus to sell iconic camera business

Sometimes, the vicissitudes of capitalism force companies to exit the businesses for which they’re best known. Olympus, once a leading light in the photography industry, is now joining that list. On Wednesday, the company said it planned to quit its 84-year-old camera business. The imaging giant, known for its once-pervasive digital cameras, agreed to sell off the declining unit by year’s end. Japan Industrial Partners, a private equity firm best known for buying Sony’s struggling Vaio computer line in 2014, agreed to purchase the business. Terms of the deal were not disclosed. A glance at Olympus’s financial statements provides all the rationale for the divestiture; as at rival manufacturers, camera sales have plummeted over the past decade. For the fiscal year ended March 31, Olympus’s camera unit declined 10% versus the year prior to  ¥43.6 billion, or $407 million. The unit’s sales have collapsed by three-quarters from a decade ago, when the company brought in ¥175 billion, or $
Post a Comment
Read more

WHO says common steroids can slash death risk for the sickest coronavirus patients

Our mission to help you navigate the new normal is fueled by subscribers. To enjoy unlimited access to our journalism,  subscribe today . An old drug can learn new tricks during the coronavirus pandemic. That’s the main takeaway from the World Health Organization (WHO) in a new analysis of corticosteroids—a class of drugs which have existed for dozens of years and are far cheaper than new, experimental COVID treatments in development—suggesting that drugs like dexamethasone can slash the chances of COVID-19 related deaths by as much as 35% in the sickest patients. The WHO analysis of coronavirus drugs encompassed seven separate studies. And while an analysis of this sort—what’s called a “meta-analysis”—isn’t as rigorous as other types of trials like a randomized controlled study, the data are compelling. Corticosteroids have a very different action mechanism from many of the other coronavirus drugs in development. COVID-19 is a peculiar disease. Some who have been infected may be
Post a Comment
Read more